Jay B. Lichter, Ph.D. is an experienced biotechnology and pharmaceutical business executive with over 25 years of experience in management, scientific research, and business development. Throughout his career, Dr. Lichter has applied his exceptional combination of business acumen and deep technical knowledge to creating commercially successful biotech companies and identifying the commercial potential of scientific discoveries at their earliest stages. Dr. Lichter is the inventor on over 260 patents and patent applications for six Avalon portfolio companies, including more than 60 issued patents. Dr. Lichter has been either directly responsible for or participated in licensing or merger and acquisition deals valued in excess of $3 billion.
Dr. Lichter led Avalon XI investments in Fortis Therapeutics and T-Rx and led Avalon X investments in AristaMD, Otonomy (NASDAQ: OTIC), SynthoRx, as well as the following investments in Sitari, Silarus, Thyritope, CadheRx, Adrenergics, Calporta, Iron Horse & PDI as part of the $495 MM strategic collaboration with GlaxoSmithKline. Dr. Lichter led Avalon investments in Afraxis, Carolus, Otonomy, Zacharon, RQx, Sova and Aratana (NASDAQ: PETX). He currently serves as a member of the board of directors for Avelas, AristaMD, SynthoRx, COI Pharmaceuticals, Carolus, Otonomy, Fortis Therapeutics, T-Rx and Sova.
Dr. Lichter held postdoctoral positions in Human Genetics at Yale University and pharmacogenetics at DuPont Merck Pharmaceutical Co. Dr. Lichter obtained his Ph.D. in biochemistry from the University of Illinois at Chicago, and a B.S. from the Univ. of Illinois at Urbana-Champaign.